Epigral Ltd.
Epigral Limited manufactures and sells chlor-alkali and related derivatives in India and internationally. The company offers chlorinated polyvinyl chloride (CPVC) resins and compounds, epichlorohydrin, chloromethanes value chain, hydrogen peroxide, caustic soda and potash, chlorine, hydrogen, chloromethanes, captive power plant (CPP), and chlorotoluene value chain, as well as operates wind-solar … Read more
Epigral Ltd. (EPIGRAL) - Total Liabilities
Latest total liabilities as of September 2025: ₹11.35 Billion INR
Based on the latest financial reports, Epigral Ltd. (EPIGRAL) has total liabilities worth ₹11.35 Billion INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Epigral Ltd. - Total Liabilities Trend (2015–2025)
This chart illustrates how Epigral Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Epigral Ltd. Competitors by Total Liabilities
The table below lists competitors of Epigral Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Groupe Guillin SA
PA:ALGIL
|
France | €321.75 Million |
|
Acrow Ltd
AU:ACF
|
Australia | AU$257.05 Million |
|
Refex Industries Limited
NSE:REFEX
|
India | ₹7.71 Billion |
|
A Paradise Acquisition Corp.
NASDAQ:APAD
|
USA | $8.47 Million |
|
Armada Acquisition Corp. II
NASDAQ:XRPN
|
USA | $13.50 Million |
|
SISB Public Company Limited
BK:SISB
|
Thailand | ฿2.24 Billion |
|
Appen Limited
PINK:APPEF
|
USA | $57.90 Million |
|
Sermsuk Public Company Limited
BK:SSC
|
Thailand | ฿4.77 Billion |
Liability Composition Analysis (2015–2025)
This chart breaks down Epigral Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.54 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Epigral Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Epigral Ltd. (2015–2025)
The table below shows the annual total liabilities of Epigral Ltd. from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹12.48 Billion | -18.98% |
| 2024-03-31 | ₹15.40 Billion | +12.99% |
| 2023-03-31 | ₹13.63 Billion | -2.47% |
| 2022-03-31 | ₹13.98 Billion | +82.81% |
| 2021-03-31 | ₹7.65 Billion | +10.81% |
| 2020-03-31 | ₹6.90 Billion | +25.12% |
| 2019-03-31 | ₹5.51 Billion | +259.21% |
| 2018-03-31 | ₹1.54 Billion | -7.43% |
| 2017-03-31 | ₹1.66 Billion | -32.24% |
| 2016-03-31 | ₹2.45 Billion | -22.05% |
| 2015-03-31 | ₹3.14 Billion | -- |